7 news items
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments
CADL
FGEN
ONCY
12 Jun 24
American Society of Clinical Oncology (ASCO) Annual Meeting, Oncolytics Biotech Inc
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments
CADL
FGEN
ONCY
12 Jun 24
American Society of Clinical Oncology (ASCO) Annual Meeting, Oncolytics Biotech Inc
Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates
BNTX
CTMX
FGEN
3 Jun 24
).
During this year's American Society of Clinical Oncology (ASCO) Annual Meeting
Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates
BNTX
CTMX
FGEN
3 Jun 24
).
During this year's American Society of Clinical Oncology (ASCO) Annual Meeting
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting
FGEN
23 May 24
prostate cancer (mCRPC) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. "We are excited
ku0icer3tzuzhm7xoxy0499u449vjhuz7ac3y401jv7
FGEN
24 Apr 24
resistant prostate cancer have been selected for a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking
i1luwgotqatr6cev3iy4trxvb d5
FGEN
2 Apr 24
at the upcoming ASCO 2024 annual meeting." Earlier data from the FOR46-001 trial had been presented at the American Society
- Prev
- 1
- Next